2017年~2019年南京地区酪氨酸激酶抑制剂类药物利用分析

doi:10.19803/j.1672-8629.2021.08.09

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (8): 743-747.
DOI: 10.19803/j.1672-8629.2021.08.09

• 新型抗肿瘤药物利用、风险性与经济性研究专栏 • 上一篇下一篇

2017年~2019年南京地区酪氨酸激酶抑制剂类药物利用分析

李友佳¹, 谢姣¹, 计成^2,*, 姚红伊³

¹西安交通大学第二附属医院药学部,陕西西安 710004;
²南京大学医学院附属鼓楼医院药学部,江苏南京 210008;
³浙江大学医学院附属第二医院药学部,浙江杭州 310009

收稿日期:2021-03-23 出版日期:2021-08-15 发布日期:2021-08-17
通讯作者: ^*计成,男,硕士,副主任药师,临床药学研究与医疗机构药事管理。E-mail：getcct@sina.com
作者简介:李友佳,女,硕士,主管药师,临床药学研究与医疗机构药事管理。
基金资助:
国家自然科学基金资助项目（82003860）; 江苏省政策引导类计划（BR2020043）; 中国药学会科技开发中心科普项目（CMEI2020KPYJ(JZX)00412）; 南京大学医院管理研究所管理项目（NDYG2019006)

Amounts of Tyrosine Kinase Inhibitors Used in Hospitals in Nanjing from 2017 to 2019

LI Youjia¹, XIE Jiao¹, JI Cheng^2,*, YAO Hongyi³

¹Department of Pharmacy, the Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an Shanxi 710004, China;
²Department of Pharmacy, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing Jiangsu 210008, China;
³Department of Pharmacy, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou Zhejiang 310009, China

Received:2021-03-23 Online:2021-08-15 Published:2021-08-17

摘要/Abstract

摘要： 目的对南京地区2017年~2019年酪氨酸激酶抑制剂类药物的临床应用情况和变化趋势进行评价。方法对南京地区36家医院2017年~2019年酪氨酸激酶抑制剂类药物的品种、销售金额、用药频度（defined daily dose system, DDDs）、限定日费用（defined daily dose cost, DDDc）等进行统计分析。结果 2017年~ 2019年南京地区36家医院酪氨酸激酶抑制剂类药物的销售金额和DDDs逐年增长,平均年增长率分别为102.42%和111.64%。吉非替尼在3年间销售金额及DDDs均处于前3位;奥希替尼、安罗替尼销售金额和DDDs增长最为明显;多数酪氨酸激酶抑制剂类药物DDDs呈增长趋势,但伊马替尼DDDs值逐年降低;达沙替尼、尼洛替尼的销售金额及排序比同步下降。结论南京地区酪氨酸激酶抑制剂类药物临床应用广泛,使用量和金额均呈快速增长趋势,大部分药物的DDDc呈降低趋势。

关键词: 酪氨酸激酶抑制剂, 销售金额, 用药频度, 限定日费用, 药物利用

Abstract: Objective To analyze the changes of usage of tyrosine kinase inhibitors in hospitals in Nanjing between 2017 and 2019. Methods The types, volume of sales, defined daily dose system (DDDs), and defined daily dose cost (DDDc) of tyrosine kinase inhibitors in 36 hospitals in Nanjing between 2017 and 2019 were analyzed statistically. Results The sales volume and DDDs of tyrosine kinase inhibitors in 36 hospitals in Nanjing increased at an average annual rate of 102.42% and 111.64% respectively between 2017 and 2019. Gefitinib remained among the top three in terms of sales amount and DDDs for three consecutive years. Osimertinib and anlotinib showed the fastest growth in sales amount and DDDs. Most of the tyrosine kinase inhibitor drugs trended up in DDDs except imatinib, the DDDs value of which decreased year by year. In addition, the sales amount and order ratio of dasatinib and nilotinib decreased simultaneously. Conclusion Tyrosine kinase inhibitors are widely used in hospitals in Nanjing, with a rapid growth rate in consumption and sales amount despite the decline in the DDDc of most of the drugs．

Key words: tyrosine kinase inhibitor, sales amount, DDDs, DDDc, drug utilization

中图分类号:

R979.1 R73

李友佳, 谢姣, 计成, 姚红伊. 2017年~2019年南京地区酪氨酸激酶抑制剂类药物利用分析[J]. 中国药物警戒, 2021, 18(8): 743-747.

LI Youjia, XIE Jiao, JI Cheng, YAO Hongyi. Amounts of Tyrosine Kinase Inhibitors Used in Hospitals in Nanjing from 2017 to 2019[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 743-747.

参考文献

[1] Zheng RS, Sun KX, Zhang SW, et al.Report of cancer epidemiology in China, 2015[J]. Chin J Oncol(中华肿瘤杂志), 2019, 41(1): 19-28.
[2] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[3] Liang YH, Huang L, Liu HG.Analysis of 618 cases reports of antitumor drug adverse reactions[J]. Northwest Pharm J(西北药学杂志), 2017, 32(5): 670-673.
[4] National Health Commission of the People's Republic of China. Guidelines for the clinical application of new anti-tumor drugs, 2019[J]. J Multidiscip Cancer Manage (Electronic Version)(肿瘤综合治疗电子杂志), 2020, 6(1): 16-47.
[5] Zhang XX, Sun LQ, Zang J.Research progress of small molecule tyrosine kinase inhibitors as antitumor agents[J]. Chin J New Drug(中国新药杂志), 2018, 27(22): 2616-2629.
[6] Chen XQ, Jin YY, Tang G.Pharmacology(新编药物学)[M]. 18th ed. Beijing: People's Medical Publishing House, 2018: 851-929.
[7] Ji C, Li J.Utilization trend of albumin and immunoglobulin biolo-gical products in hospitals of nanjing during 2016-2018[J]. Chin J Pharmacoepidem(药物流行病学杂志), 2020, 29(7): 484-487.
[8] Chang QQ, Peng Y, Wang GJ, et al.Clinical research progress of small molecule tyrosine kinase inhibitors as anti-hepatocellular carcinoma agents[J]. Chin J Clin Pharm Th(中国临床药理学与治疗学), 2019, 24(8): 948-956.
[9] Choi YJ, Park GM, Rho JK, et al.Role of IGF-binding protein 3 in the resistance of EGFR mutant lung cancer cells to EGFR-tyrosine kinase inhibitors[J]. PLoS One, 2013, 8(12): e81393.
[10] Fang WT, Luo C, Dai HZ, et al.Application analysis and medicare payments prediction of new selected anti-tumor drugs of medical insurance in Nanjing city[J]. Chin J Hosp Pharm(中国医院药学杂志), 2018, 38(11): 1131-1137.
[11] Liu ZH, Luo MH, Zou AM, et al.Clinical observation of molecular targeted therapy with gefitinib for advanced lung adenocarcinoma[J]. Chin J Mod Drug Appl(中国现代药物应用), 2020, 14(21): 121-122.
[12] Ettinger DS, Wood DE, Aggarwal C, et al.NCCN guidelines insights: non-small cell lung cancer, version 1. 2020[J]. J Natl Compr Canc Netw, 2019, 17(12): 1464-1472.
[13] Huang Y, Zhang L.Interpretation of the updated key points of the CSCO non-small cell lung cancer diagnosis and treatment guidelines, 2020[J]. J Clin Internal Med(临床内科杂志), 2020, 37(8): 603-605.
[14] Wang J, Zhao Y, Wang Q, et al.Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third or further-line treatment[J]. Cancer Biol Med, 2018, 15(4): 443-451.
[15] Chinese Association for Clinical Oncologists, Expert Committee of Vascular Targeted Therapy of Chinese Society of Clinical Oncology, Cancer Targeted Therapy Professional Committee of China Anti-Cancer Association. Chinese expert consensus on anlotinib hydrochloride for advanced lung cancer (2020 edition)[J]. Chin J Onclo(中华肿瘤杂志), 2020, 42(10): 807-816.
[16] Yan GT, Hu JP, Zhang YT, et al.Market analysis of imatinib mesylate[J]. Coal Chem Ind(煤炭与化工), 2013, 36(6): 44-45, 74.
[17] Cao HZ, Sun H, Sun YX, et al.Research progress in the correlation between miRNA and imatinib resistance[J]. Chinese Bulletin of Life Sciences(生命科学), 2020, 36(6): 581-589.

2017年~2019年南京地区酪氨酸激酶抑制剂类药物利用分析

Amounts of Tyrosine Kinase Inhibitors Used in Hospitals in Nanjing from 2017 to 2019

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 13

编辑推荐

Metrics

[1]	殷进军, 王淑伟, 邵姜超, 王冰. 基于加权TOPSIS法的贝伐珠单抗注射液药物利用评价[J]. 中国药物警戒, 2023, 20(12): 1421-1426.
[2]	俞吉, 冉烁. 药物利用评价和药物利用评估法评价ST段抬高心肌梗死临床路径患者的用药情况[J]. 中国药物警戒, 2022, 19(6): 674-679.
[3]	胡章海, 杨万枝. 基于加权逼近理想解排序法的儿科利奈唑胺药物利用评价[J]. 中国药物警戒, 2022, 19(10): 1128-1131.
[4]	王晓, 何璇, 戴惠珍, 李歆, 韩峰. 基于终端数据的南京地区抗肿瘤新药市场竞争趋势分析[J]. 中国药物警戒, 2021, 18(8): 731-736.
[5]	何璇, 王晓, 戴惠珍, 李歆, 韩峰. 2018年~2020年南京地区新型抗肿瘤药物利用分析[J]. 中国药物警戒, 2021, 18(8): 725-730.
[6]	梁银武, 邹剑. 基于加权TOPSIS法的伏立康唑注射剂药物利用评价[J]. 中国药物警戒, 2018, 15(3): 186-189.
[7]	李海龙, 赵厚宇, 林鸿波, 刘翠丽, 沈鹏, 詹思延. 鄞州区门诊利巴韦林注射剂18至44岁育龄使用者用药情况分析[J]. 中国药物警戒, 2018, 15(2): 78-82.
[8]	林鸿波, 刘翠丽, 沈鹏, 李海龙, 赵厚宇, 詹思延. 基于鄞州区域医疗数据的利巴韦林临床使用的分析[J]. 中国药物警戒, 2018, 15(2): 73-77.
[9]	左拥军,李永兵. 我院2011～2012年门诊癌症患者麻醉药品使用分析[J]. 中国药物警戒, 2013, 10(7): 419-420.
[10]	吴健,高家荣,李颖,汪永忠. 142例美罗培南临床应用分析研究[J]. 中国药物警戒, 2013, 10(4): 249-251.
[11]	王玉娉. 我院2009~2011年二类精神药品的应用情况分析[J]. 中国药物警戒, 2012, 9(8): 500-502.
[12]	胡文俊，周丽琼，黄文涛，秦绍金. 我院2008~2010 年麻醉药品应用分析[J]. 中国药物警戒, 2012, 9(1): 35-37.
[13]	林志强, 张国伟, 王大璇, 傅新阳, 龚海虹. 我院细菌耐药率变迁与抗菌药物用量的相关性研究[J]. 中国药物警戒, 2011, 8(2): 75-80.